Inactive Instrument

News MediGene AG Other OTC

Equities

DE0005020903

End-of-day quote Other OTC Other stock markets
- ^USD	-

27/06	Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness	CI
21/05	Medigene, BioNTech Extend Cancer Immunotherapy Partnership	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness	27/06	GL
Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness	27/06	CI
Medigene Reports Results of Annual General Meeting	24/06	GL
Medigene to Present at the Cell and Gene Therapy In-Depth Focus Summit 2024	21/06	GL
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumors	20/06	GL
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumors	20/06	AQ
Medigene : Expands its End to End Platform by Submitting Three Patents to the European Patent Office	19/06	PU
Medigene : Release according to Article 40, Section 1 of the WpHG	19/06	PU
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office	28/05	GL
Medigene, BioNTech Extend Cancer Immunotherapy Partnership	21/05	MT
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term	21/05	GL
Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term	21/05	CI
Medigene : Description of the remuneration system for Supervisory Board members	17/05	PU
Medigene : Report of the Executive Board on agenda item 8	17/05	PU
Medigene : Report of the Executive Board on agenda item 9	17/05	PU
Medigene : Explanations of the rights of shareholders	17/05	PU
Medigene : Proxy to third person	17/05	PU
Medigene : Data protection information	17/05	PU
Medigene : CV Dr. Gerd Zettlmeissl	17/05	PU
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	15/05	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News MediGene AG Other OTC

Equities

DE0005020903

Summary

Filters